Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency.

Hussain RZ, Cravens PC, Doelger R, Dentel B, Herndon E, Loof N, Tsai P, Okuda DT, Racke MK, Stüve O.

Ann Clin Transl Neurol. 2018 Oct 30;5(12):1543-1561. doi: 10.1002/acn3.664. eCollection 2018 Dec.

2.

PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.

Dubey D, Hussain RZ, Miller-Little WA, Salter A, Doelger R, Stüve O.

J Neuroimmunol. 2018 Oct 15;323:53-55. doi: 10.1016/j.jneuroim.2018.07.012. Epub 2018 Jul 25.

PMID:
30196834
3.

Similar Biophysical Abnormalities in Glomeruli and Podocytes from Two Distinct Models.

Embry AE, Liu Z, Henderson JM, Byfield FJ, Liu L, Yoon J, Wu Z, Cruz K, Moradi S, Gillombardo CB, Hussain RZ, Doelger R, Stuve O, Chang AN, Janmey PA, Bruggeman LA, Miller RT.

J Am Soc Nephrol. 2018 May;29(5):1501-1512. doi: 10.1681/ASN.2017050475. Epub 2018 Mar 23.

PMID:
29572404
4.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

5.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
6.

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.

Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O.

PLoS One. 2016 Oct 25;11(10):e0165248. doi: 10.1371/journal.pone.0165248. eCollection 2016.

7.

Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Deason K, Castro-Rojas C, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):9-17. doi: 10.1016/j.jneuroim.2014.08.622. Epub 2014 Aug 30. Review.

8.

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.

Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):232-5. doi: 10.1016/j.jneuroim.2014.08.624. Epub 2014 Sep 2.

9.

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.

Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M.

J Exp Med. 2011 Oct 24;208(11):2291-303. doi: 10.1084/jem.20100977. Epub 2011 Oct 10.

10.

Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.

Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O.

J Neuroinflammation. 2011 Jun 24;8:73. doi: 10.1186/1742-2094-8-73.

11.

Silencing Nogo-A promotes functional recovery in demyelinating disease.

Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben LH, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, McTigue DM, Lovett-Racke AE.

Ann Neurol. 2010 Apr;67(4):498-507. doi: 10.1002/ana.21935.

12.

Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O.

Brain. 2010 Feb;133(Pt 2):375-88. doi: 10.1093/brain/awp298. Epub 2010 Feb 9.

13.

Direct and consensual murine pupillary reflex metrics: establishing normative values.

Hussain RZ, Hopkins SC, Frohman EM, Eagar TN, Cravens PC, Greenberg BM, Vernino S, Stüve O.

Auton Neurosci. 2009 Dec 3;151(2):164-7. doi: 10.1016/j.autneu.2009.07.021. Epub 2009 Aug 15.

14.

Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease.

Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK.

J Immunol. 2009 Apr 1;182(7):4479-87. doi: 10.4049/jimmunol.0713927.

15.

CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE.

Yang Y, Ratts RB, Hussain RZ, Northrop SC, Ben LH, Lovett-Racke A, Racke MK.

Eur J Immunol. 2007 Jul;37(7):2032-42.

16.

T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.

Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE.

J Immunol. 2007 Feb 1;178(3):1341-8.

17.

Phenotypic characterization of autoreactive T cells in multiple sclerosis.

Ratts RB, Karandikar NJ, Hussain RZ, Choy J, Northrop SC, Lovett-Racke AE, Racke MK.

J Neuroimmunol. 2006 Sep;178(1-2):100-10. Epub 2006 Aug 8.

PMID:
16901549
18.

CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.

Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ, Racke MK.

J Neuroimmunol. 2006 Sep;178(1-2):117-29. Epub 2006 Jul 11.

PMID:
16837065
19.

Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity.

Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK.

J Neuroimmunol. 2006 Mar;172(1-2):94-103. Epub 2005 Dec 20.

PMID:
16360885
20.

Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.

Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, Sikder D, Racke MK.

Immunity. 2004 Nov;21(5):719-31.

21.

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK.

J Immunol. 2004 May 1;172(9):5790-8.

22.
23.
25.

Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis.

Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD, Racke MK.

J Immunol. 2002 Mar 1;168(5):2508-15.

Supplemental Content

Loading ...
Support Center